A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs ELVN-001 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Enliven Therapeutics
- 29 Jan 2025 New trial record